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Purpose: The purpose of this study was to investigate whether
preemptive dosing with lumiracoxib is more effective than post-
operative dosing in reducing post-operative pain associated with
ambulatory arthroscopic knee surgery.
Methods: A multicenter, randomized, double-blind, placebo con-
trolled, parallel group study comparing lumiracoxib 400 mg given
preemptively versus post-operatively in adult patients undergo-
ing minor ambulatory arthroscopic knee surgery (e.g. removal,
trimming, shaving or repair of meniscal or articular cartilage
including lavage). Eligible patients were randomized to either
lumiracoxib 400 mg given preemptively (1 hour before start of
surgery); lumiracoxib 400 mg given post-operatively (15 minutes
after the completion of surgery); and placebo in a 2:2:1 ratio.
The primary endpoint was the pain intensity (PI) after movement
in the target knee 2 hours after surgery based on a 0-100 mm
Visual Analog Scale (VAS) using Wilcoxon rank sum test. The
secondary endpoints included time to rescue medication intake,
PI at 1, 2, 3, 4 and 24 hours while at rest, and PI at 1, 3, 4 and
24 hours after movement, and both measured on a 0-100 mm
VAS using Logrank test.
Results: In total, 110 patients were randomized (lumiracoxib pre-
emptive n=45, lumiracoxib post-operative n=44, placebo n=21),
and all patients completed the study. The difference in me-
dian PI after movement at 2 hours in the lumiracoxib preemp-
tive group (PI=2.75) compared to the lumiracoxib post-operative
group (PI=3.50) in the intent-to-treat (ITT) population was 0.0
(95%CI: -2,1), p=0.602; while lumiracoxib preemptive and post-
operative groups compared to the placebo (PI=9) were -4.0
(95%CI: -9,-1), p=0.007 and -3.5 (95%CI: -8.5,0), p=0.052 re-
spectively.
The time to rescue medication intake was signiﬁcantly longer
for lumiracoxib preemptive (p=0.003) and post-operative groups
(p=0.001) compared to placebo using Logrank test (Figure 1).
The difference in median PI (at rest) post-surgery was not statis-
tically signiﬁcant between the lumiracoxib preemptive group and
Figure 1. Time-to-ﬁrst rescue medication (ITT population).
the post-operative group at any timepoints (1, 2, 3, 4 and 24
hours).
The difference in median PI (at rest) post-surgery for lumiracoxib
preemptive and post-operative groups compared to the placebo
was statistically signiﬁcant at 2, 3, 4 and 24 hours.
The difference in median PI (after movement) post-surgery was
not statistically signiﬁcant between the lumiracoxib preemptive
group and the post-operative group at any timepoints (1, 3, 4
and 24 hours).
The difference in median PI (after movement) post-surgery for
lumiracoxib preemptive and post-operative groups compared to
placebo was statistically signiﬁcant at 1, 3, 4 and 24 hours.
The proportion of patients with adverse events (AEs) were similar
for lumiracoxib preemptive (4.4%), post-operative (4.5%) and
placebo (4.8%), with no serious AEs reported.
Conclusions: Preemptive or postoperative dosing of lumiracoxib
400 mg od had similar efﬁcacy in reducing post-operative pain
following ambulatory arthroscopic knee surgery
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Purpose: An autologous preparation rich in growth factors
(PRGF) secretes a complex mixture of biological mediators es-
sential for natural repair, including TGF-ß1, PDGF, VEGF, HGF
and IGF-I. Due to the localized nature of OA, the possibility of
intra-articular administration of PRGF, along with its biocompati-
bility and non-immunogenicity, may make this unique molecular
mixture an attractive treatment for OA.
Purpose: (1) To explore the potential clinical beneﬁts of PRGF
injections for the treatment of OA in a retrospective observational
study. (2) To characterize the PRGF treatment in OA patients.
Methods: A total of 112 patients with symptomatic knee OA were
treated with a series of three weekly intra-articular injections
of PRGF and studied retrospectively. Anterio-posterior weight-
bearing radiographs were scored for Ahlbäck severity grade.
In bilateral patients, the Ahlbäck grade used for analyses was
the higher of the two knees. The primary efﬁcacy criteria were
mean change from baseline through two and six months in the
WOMAC index pain and physical function subscale scores and
global WOMAC assessment at month two and six. A repeated
measures ANCOVA model was used to compare clinical parame-
ters at baseline and at follow-up. Age, gender, Ahlbäck grade and
BMI were included in the models. Success rates were calculated
as a reduction in the WOMAC pain score of at least 40% from
baseline and a 35% reduction in the physical function and global
WOMAC scores. For preparation of the PRGF treatment, unco-
agulated peripheral blood was collected from the patient; after
one single-step centrifugation, the plasma fraction located just
above the buffy coat was aspirated and dispensed into an empty
tube under vertical air ﬂow conditions. Platelet activation was in-
duced by CaCl2 addition a few minutes prior to PRGF inﬁltration.
Enzyme-linked immunosorbent assays were used for determin-
ing levels of PDGF-AB, VEGF, HGF, IGF-I and TGF-β1 in PRGF.
Results: The mean age of the participants was 67 years (range:
42-91). Of the participants, 63% were female and the average
BMI was 28 kg/m2 (range: 21-40). Of the 112 knee radiographs
included in the study, twenty-three (20%) were graded Ahlbäck I,
50 (45%) were graded Ahlbäck II, 29 (26%) were graded Ahlbäck
III and 10 (9%) were graded Ahlbäck IV. The differences between
pain subscale scores at baseline and two or six months were
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highly signiﬁcant (-1.766, 95% CI: -1.073 to -2.458, p=0.000,
n=112; and -2.320, CI: -3.838 to -0.803, p=0.011, n=41) The ob-
served success rates for the pain subscale reached 37% by two
months and 31.7% by six months. Two months after treatment
initiation, WOMAC physical function subscale scores and global
assessment decreased signiﬁcantly (-4.772, 95% CI: -6.864 to
-2.681, p=0.000; -7.105, 95% CI: -9.936 to -4.274, p=0.013). The
changes at six months were not statistically signiﬁcant (n=41 pa-
tients). The success rates for the physical function subscale and
global WOMAC index were 31.4% and 34.5% by two months
(n=112) and 31.7% and 34.1% by six months (n=41).
The PRGF treatment performed as described above resulted
in a moderate enrichment in platelet number; a 2.0 ± 0.5-fold
increase compared to peripheral blood. The levels of the main
platelet secretory growth factors were 27.28 ± 10.90 ng/cc for
TGF-β1 and 15.66 ± 8.02 ng/cc for PDGF. VEGF was also se-
creted from platelets but was less abundant. Other GFs present
in PRGF reﬂect mainly plasma levels; among these growth fac-
tors are IGF-I (55.53 ± 20.87 ng/cc) and the less concentrated
HGF (472 ± 221 pg/cc).
Conclusions: Continued research on autologous therapies
might yield a new therapeutic option for OA treatment in se-
lected patients
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Purpose: Previous studies have shown that Non-Steroidal Anti-
Inﬂammatory Drugs (NSAIDs) may inhibit the antihypertensive
effect of Angiotensin Converting Enzyme Inhibitors (ACEIs). We
studied whether lumiracoxib 100 mg od would have less impact
on 24-hour mean ambulatory blood pressure (MABP) compared
to ibuprofen 600 mg tid in osteoarthritis (OA) patients with con-
trolled hypertension treated with ACEI monotherapy.
Methods: This was a 4-week, multicenter, randomized, double-
blind, double-dummy, parallel group study of hypertensive OA
patients aged ≥50 years (ofﬁce blood pressure (BP) <140/90
mmHg) on stable antihypertensive treatment. All subjects were
randomized to take either lumiracoxib 100 mg od or ibuprofen 600
mg tid (1:1). The main outcome measure was the change from
baseline in 24-hour systolic MABP at 4 weeks. Other measures
included change from baseline in 24-hour diastolic MABP as well
as daytime and night-time systolic and diastolic MABP. Here,
we report a post-hoc subgroup analysis of subjects taking ACEI
monotherapy for hypertension.
Results: Of the 787 patients randomized in the study, 82 were
taking ACEI monotherapy. 42 were randomized to lumiracoxib
and 40 to ibuprofen. The change from baseline (least square [LS]
means) in 24-hour systolic MABP was -4.6 mmHg for lumiracoxib
and +3.7 mmHg with ibuprofen at 4 weeks, estimated treatment
difference -8.2 mmHg [95% CI -12.1,-4.4], p<0.001. The change
from baseline (LS means) in 24-hour diastolic MABP was - 2.0
mmHg for lumiracoxib and +2.0 mmHg for ibuprofen at 4 weeks,
estimated treatment difference -4.0 mmHg [95% CI -6.6, -1.4],
p=0.003). This compared with a difference in 24-hour systolic
MABP of -5.0 mmHg [95% CI -6.1,-3.8], p<0.001) and diastolic
MABP of -2.0 mmHg [95% CI -2.7,-1.3], p<0.001) in the overall
patient population. For the LS mean change from baseline in
daytime and night-time systolic MABP, the estimated treatment
differences were -9.4 mmHg [95% CI -13.9,-4.9], p<0.001 and
-5.4 mmHg [95% CI -9.4,-1.4], p=0.008. Similar results were
obtained for the LS mean change from baseline in daytime and
night-time diastolic MABP, with estimated treatment differences
of -4.3 mmHg [95% CI -7.4,-1.1], p=0.009 and -2.8 mmHg [95%
CI -5.7,-0.0], p=0.049.
Conclusions: Lumiracoxib 100 mg od resulted in less destabi-
lization of BP compared with ibuprofen 600 mg tid in controlled
hypertensive OA patients treated with ACEI monotherapy. Ac-
cording to this post-hoc analysis, treatment differences may be
more pronounced in patients using ACEI monotherapy. Whilst
these ﬁndings are not deﬁnitive, they point to important dif-
ferences in the effect of different NSAIDs on BP control in
hypertensive osteoarthritis patients who are taking ACEIs.
266
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Purpose: Unicompartmental arthroplasty may provide better al-
ternative for physiological function, quicker recovery and long-
term satisfaction compared to TKA and repeat arthroscopic inter-
ventions. The purpose of this study was to prospectively evaluate
outcomes following unicompartmental knee arthroplasty as well
as predictors for patient satisfaction.
Methods: 62 consecutive patients were prospectively studied
(45 medial replacements, 17 lateral replacements)] underwent
unicompartmental arthroplasty from 2000-2005. There were 34
males and 49 females [average age of 69.87 (range 40-92)].
Eighty-six percent had at least 2 year follow-up. Assessment
included preoperative and postoperative range of motion, sub-
jective questionnaire, KT-1000, plain radiograph knee series in-
cluding 3-foot alignment ﬁlms. A 1.5-Tesla MRI was completed in
all patients but one who had a pacemaker.
Results: All patients reported severe knee pain preoperatively
involving one compartment. One patient died. Two patients were
converted to a total knee arthroplasty (medial replacements).
Average follow-up was 33 months (range: 24-56 months). The
average post-surgical Lysholm score was 91 (range 62 to 100),
with a preoperative Lysholm of 57 (range 31 to 92) (p=0.001).
The Tegner activity score improved from 2.8 (1 to 7) preopera-
tively to 4(1 to 8) postoperative(p=0.001). The preoperative HSS
score improved from 67(45 to 87) to 92 (77 to 100)(p=0.001). For
patients who underwent medial replacements, they had lower
preoperative Lysholm (42 vs. 57) if they had grade 3 or 4 degen-
erative changes, as read on the MRI, in the lateral compartment;
however, there was not difference in post-op Lysholm (89 vs
92;p=0.419). This was also seen in patients with grade 3 or 4
degenerative changes in the medial compartment that underwent
lateral replacement. Age was correlated with post-operative Teg-
ner scores(r=-0.586, p=0.001). Independent predictor of patient
satisfaction was postoperative Tegner score (r2=0.26; p=0.04).
Conclusions: Determining speciﬁc patient selection criteria im-
proves patient outcomes and helps with patient education. This
study demonstrates that patients can return to high level of func-
tion and activity following unicompartmental arthroplasty. The
presence of degenerative changes seen on MRI on the opposite
compartment does not correlate to decreased function or activity.
Patient satisfaction is high and it related to activity level, which
this type of arthroplasty allows for more high level activities.
